Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants.

Kenneth A Bauer1

  • 1VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. kbauer@bidmc.harvard.edu

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Population-Scale Studies of Protein S Abnormalities and Thrombosis.

JAMA·2025
Same author

Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation.

Blood advances·2025
Same author

Splanchnic vein thrombosis: management for the thrombosis specialist.

Journal of thrombosis and haemostasis : JTH·2024
Same author

Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank.

Blood·2024
Same author

The dos, don'ts, and nuances of thrombophilia testing.

Hematology. American Society of Hematology. Education Program·2023
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

New anticoagulants like direct thrombin and factor Xa inhibitors offer improved predictability over traditional drugs. Fondaparinux shows efficacy and reduced bleeding in VTE treatment, with new oral agents in development.

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiology

Background:

  • Traditional anticoagulants (heparin, warfarin) have limitations.
  • New anticoagulants target single coagulation factors for predictable responses.
  • These include direct thrombin and factor Xa inhibitors.

Purpose of the Study:

  • Review the development and status of novel anticoagulants.
  • Highlight approved agents and those in clinical development.
  • Discuss challenges in clinical trial design for new anticoagulants.

Main Methods:

  • Review of FDA-approved anticoagulants (lepirudin, argatroban, bivalirudin, fondaparinux).
  • Analysis of clinical trial data (e.g., OASIS 5 trial for fondaparinux).
  • Assessment of oral direct thrombin and factor Xa inhibitors in development.

Related Experiment Videos

Main Results:

  • Parenteral direct thrombin inhibitors are approved for HIT and PCI.
  • Fondaparinux is effective for VTE prevention/treatment, showing reduced bleeding vs. enoxaparin in ACS.
  • Oral anticoagulants show promise but face development hurdles.

Conclusions:

  • Novel anticoagulants offer targeted mechanisms and improved safety profiles.
  • Fondaparinux represents a significant advancement in VTE management.
  • Ongoing research focuses on developing safe and effective oral anticoagulants for thrombosis prevention and treatment.